Wolfram E. Samlowski
Affiliations: | University of Utah, Salt Lake City, UT |
Area:
Immunology, Molecular BiologyGoogle:
"Wolfram Samlowski"Children
Sign in to add trainee| Muralidhar Kondapaneni | grad student | 2007 | University of Utah |
| Yetty Y. Irwan | grad student | 2010 | University of Utah |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Samlowski WE, Moon J, Witter M, et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Medicine |
| Gill DM, Stenehjem DD, Parikh K, et al. (2016) Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience. 10: 676 |
| Stenehjem DD, Toole M, Merriman J, et al. (2016) Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunology, Immunotherapy : Cii |
| Samlowski WE, Wojcik J, Samlowski S, et al. (2016) Case Report: Pazopanib Treatment Response in a Patient with Metastatic Pleomorphic Dermal Sarcoma (Atypical Fibroxanthoma) with Circulating Tumor Cell-Derived Colonies as a Predictive Marker Journal of Cancer Therapy. 7: 785-793 |
| Stenehjem DD, Toole M, Merriman J, et al. (2015) Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 33: 4565-4565 |
| Samlowski WE, McGregor JR, Samlowski ST, et al. (2014) Growth of Circulating Tumor Cell-Derived Colonies from Peripheral Blood of Melanoma Patients: Preliminary Characterization of Colony Composition Health. 6: 1467-1481 |
| Batten JA, Samlowski WE, Parikh K, et al. (2014) Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 487-487 |
| Stenehjem DD, Parikh K, Batten JA, et al. (2014) Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 476-476 |
| Agarwal N, Parikh K, Tantravahi SK, et al. (2014) Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 32: 461-461 |
| Parikh K, Stenehjem DD, Sendilnathan A, et al. (2014) Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 460-460 |